• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal

    1/10/24 2:29:00 PM ET
    $TENK
    Blank Checks
    Finance
    Get the next $TENK alert in real time by email

    New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "Company"), announced today that if the proposal to amend the Company's Amended and Restated Memorandum and Articles of Association, which provides that the Company may elect to extend the date by which the Company has to consummate a business combination for a total of eight (8) times, as follow: (i) one (1) time for an additional three (3) months from January 18, 2024 to April 18, 2024, and subsequently (iii) seven (7) times for an additional one (1) month each time from April 18, 2024 to November 18, 2024 (the "Extension Amendment Proposal"), is approved at the Company's previously announced extraordinary general meeting (the "Meeting") and the extension is implemented, its sponsor, 10XYZ Holdings LP, or its sponsor's designees will contribute to the Company as a loan, the lesser of (a) $200,000 or (b) $0.10 per public share that is not redeemed, for the additional three (3) month extension from January 18, 2024 to April 18, 2024 and the lesser of (x) $66,667 or (y) $0.03 per public share that is not redeemed, for each month during the subsequent additional one (1) month extensions from April 18, 2024 to November 18, 2024 ("Contribution"), that is needed to complete an initial business combination.

    Each Contribution will be deposited in the Company's trust account on or prior to the date of the applicable deadline. Any Contribution is conditioned upon the implementation of the Extension Amendment Proposal. No Contribution will occur if the Extension Amendment Proposal is not approved. The amount of each Contribution will not bear interest to the sponsor as a loan and will be repayable by the Company to the sponsor or its designees upon consummation of the business combination. If the Company opts not to utilize any remaining portion of the extensions, then the Company will liquidate and dissolve promptly in accordance with its Amended and Restated Memorandum and Articles of Association, and the sponsor's obligation to make additional contributions will terminate.

    The record date for determining the Company shareholders entitled to receive notice of and to vote at the Meeting remains the close of business on December 28, 2023 (the "Record Date"). Shareholders as of the Record Date can vote, even if they have subsequently sold their shares. Shareholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action. Shareholders who have not yet done so are encouraged to vote as soon as possible.

    Shareholders who wish to withdraw their previously submitted redemption request may do so prior to the Meeting by requesting that the Company's transfer agent return such shares by 5:00 p.m. Eastern Time on January 12, 2024. If any such shareholders have questions or need assistance in connection with the Meeting, please contact the Company's proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, 22nd Floor, New York, New York 10005, Call Toll Free: (800) 714-3310, Banks and Brokers Call Collect: (212) 269-5550, Email: [email protected].

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as "believes," "expects," "intends," "plans," "estimates," "assumes," "may," "should," "will," "seeks," or other similar expressions. Such statements may include, but are not limited to, statements regarding the Meeting and the proposed Contribution. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

    Additional Information and Where to Find It

    On January 8, 2024, the Company filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") in connection with its solicitation of proxies for the Meeting. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the definitive proxy statement (including any amendments or supplements thereto) and other documents filed with the SEC through the web site maintained by the SEC at www.sec.gov or by directing a request to the Company's proxy solicitor at D.F. King & Co., Inc., 48 Wall Street, 22nd Floor, New York, New York 10005, Call Toll Free: (800) 714-3310, Banks and Brokers Call Collect: (212) 269-5550, Email: [email protected] or to the Company at its principal executive offices at 420 Lexington Avenue, Suite 2446, New York, NY 10170, telephone: 347-627-0058.

    Participants in the Solicitation

    The Company and its respective directors and officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Meeting. Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the definitive proxy statement. You may obtain free copies of these documents using the sources indicated above.

    Contact

    Taylor Zhang

    Chief Financial Officer

    Email: [email protected]

    Tel: (347) 627-0058



    Primary Logo

    Get the next $TENK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TENK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TENK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Dutia Suren G

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    8/14/24 6:29:05 PM ET
    $TENK
    Blank Checks
    Finance

    SEC Form 4 filed by Director Holubiak Myron Z

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    8/14/24 6:28:37 PM ET
    $TENK
    Blank Checks
    Finance

    SEC Form 4 filed by Chief Medical Officer Czuczman Myron

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    8/14/24 6:28:05 PM ET
    $TENK
    Blank Checks
    Finance

    $TENK
    SEC Filings

    View All

    SEC Form 25-NSE filed by TenX Keane Acquisition

    25-NSE - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

    8/13/24 4:33:39 PM ET
    $TENK
    Blank Checks
    Finance

    SEC Form 10-Q filed by TenX Keane Acquisition

    10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    8/9/24 4:22:23 PM ET
    $TENK
    Blank Checks
    Finance

    TenX Keane Acquisition filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - TenX Keane Acquisition (0001851484) (Filer)

    8/2/24 8:45:17 PM ET
    $TENK
    Blank Checks
    Finance

    $TENK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

    TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) ("TenX"), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 202

    8/9/24 7:30:00 AM ET
    $CTXR
    $TENK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Blank Checks
    Finance

    TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

    TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition company, today announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly own

    8/5/24 8:00:00 AM ET
    $CTXR
    $TENK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Blank Checks
    Finance

    Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

    Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction    Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane

    8/5/24 8:00:00 AM ET
    $CTXR
    $TENK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Blank Checks
    Finance

    $TENK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by TenX Keane Acquisition

    SC 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

    8/15/24 12:53:48 PM ET
    $TENK
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by TenX Keane Acquisition (Amendment)

    SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

    3/7/24 4:06:26 PM ET
    $TENK
    Blank Checks
    Finance

    SEC Form SC 13G filed by TenX Keane Acquisition

    SC 13G - TenX Keane Acquisition (0001851484) (Subject)

    2/13/24 8:09:57 PM ET
    $TENK
    Blank Checks
    Finance